Potential treatment for fibrosis

Md Nurunnabi, Ph.D., is an associate professor in UTEP's School of Pharmacy and the lead researcher on two studies published this June in the medical Journal of Controlled Release; one study focuses on skin fibrosis and the other on lung fibrosis.

"We are closer than ever to developing a safe, effective and reliable approach to treating fibrosis," Nurunnabi said.

Fibrosis is a condition in which the tissues in an organ -- such as the skin, lungs, liver or kidneys -- become thicker and stiffer, according to Nurunnabi. This can have multiple damaging effects, such as the lungs not being able to hold enough oxygen or blood vessels becoming narrower, leading to high blood pressure.

"I studied fibrosis during my postdoctoral training but became interested in focusing on it in my lab during the COVID-19 pandemic," Nurunnabi said. "I observed that many people were passing away not because of COVID itself, but because of the inflammation and fibrosis caused by the viral infection in the lungs. Our lab focuses on developing nanotechnology that can target specific cells."

Fibrosis can occur as a side effect of chemotherapy or the result of a viral infection or autoimmune disease, a condition in which the body's immune system attacks its own cells. For example, with an autoimmune condition, the body kills cells called fibroblasts that help form connective tissue. The body then produces more collagen than it needs, which leads to fibrosis.

Nurunnabi's team focused on designing a nanoparticle that could target the cells that are responsible for fibrosis development and progression without disturbing the "good" cells necessary for the body's healthy functioning. Rather than killing the "bad" cells, the team was successful in modifying them so that they no longer produced excess collagen, in effect rehabilitating the cells. The studies were conducted in the test tube and in mice.

"Dr. Nurunnabi's research into skin and lung fibrosis sheds light on the devastating impact of these conditions, whether acute or chronic," said José Rivera, Pharm.D, founding dean of the School of Pharmacy. "His findings offer hope for improved treatments that could significantly increase life expectancy and enhance the quality of life for affected individuals."

Nurunnabi's lab is funded through a collaborative program between UTEP, the National Institutes of Health and Baylor College of Medicine, as well as a pilot grant from the National Scleroderma Foundation to conduct research related to treatment of fibrosis.